Intranasal zavegepant for the acute treatment of migraine.

Autor: Greco G; Department of Neurology, Headache Division, Miami, FL, USA., Monteith T; Department of Neurology, Headache Division, Miami, FL, USA.

Publikováno v: Expert review of neurotherapeutics [Expert Rev Neurother] 2024 Dec; Vol. 24 (12), pp. 1131-1140. Date of Electronic Publication: 2024 Sep 23.

Ubrogepant users' real-world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study.

Autor: Shewale AR; AbbVie, North Chicago, Illinois, USA., Poh W; Healint Pte Ltd, Singapore, Singapore., Reed ML; Vedanta Research, Chapel Hill, North Carolina, USA., Liu J; Genesis Research, Hoboken, New Jersey, USA., Cadiou F; Healint Pte Ltd, Singapore, Singapore., Ezzati A; Department of Neurology, University of California, Irvine, California, USA., Burslem K; AbbVie, North Chicago, Illinois, USA., Manthena S; AbbVie, North Chicago, Illinois, USA., Lipton RB; The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.

Publikováno v: Headache [Headache] 2024 Nov-Dec; Vol. 64 (10), pp. 1244-1252. Date of Electronic Publication: 2024 Sep 26.

Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists.

Autor: Staas DD; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Bell IM; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA. Electronic address: ian_bell@merck.com., Burgey CS; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Deng JZ; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Gallicchio SN; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Lim JJ; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Paone DV; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Potteiger CM; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Shaw AW; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Stevenson H; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Stump CA; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Blair Zartman C; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Moore EL; Department of Neuroscience, Merck & Co., Inc., West Point, PA 19486, USA., Bruno JG; Department of In Vitro Pharmacology, Merck & Co., Inc., West Point, PA 19486, USA., Mosser SD; Department of In Vitro Pharmacology, Merck & Co., Inc., West Point, PA 19486, USA., White RB; Department of Drug Metabolism & Pharmacokinetics, Merck & Co., Inc., West Point, PA 19486, USA., Kane SA; Department of Neuroscience, Merck & Co., Inc., West Point, PA 19486, USA., Salvatore CA; Department of Neuroscience, Merck & Co., Inc., West Point, PA 19486, USA., Graham SL; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Williams TM; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Selnick HG; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA., Fraley ME; Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2024 Nov 01; Vol. 112, pp. 129944. Date of Electronic Publication: 2024 Sep 02.

Combining treatments for migraine prophylaxis: the state-of-the-art.

Autor: Pellesi L; Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Campusvej 55, Odense, 5230, Denmark. lpellesi@health.sdu.dk., Garcia-Azorin D; Department of Medicine, Toxicology and Dermatology, Faculty of Medicine, University of Valladolid, Valladolid, Spain.; Department of Neurology, Hospital Universitario Río Hortega, Valladolid, Spain., Rubio-Beltrán E; Headache Group, Wolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom., Ha WS; Department of Neurology, Yonsei University College of Medicine, Seoul, Korea., Messina R; Neuroimaging Research Unit and Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Ornello R; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Petrusic I; Laboratory for Advanced Analysis of Neuroimages, Faculty of Physical Chemistry, University of Belgrade, Belgrade, Serbia., Raffaelli B; Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany., Labastida-Ramirez A; Division of Neuroscience, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom., Ruscheweyh R; Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany., Tana C; Center of Excellence on Headache, Geriatrics Clinic, Ss. Annunziata of Chieti, Italy., Vuralli D; Department of Neurology and Algology, Faculty of Medicine, Gazi University, Ankara, Türkiye.; Neuropsychiatry Center, Gazi University, Ankara, Türkiye.; Neuroscience and Neurotechnology Center of Excellence (NÖROM), Gazi University, Ankara, Türkiye., Waliszewska-Prosół M; Department of Neurology, Wroclaw Medical University, Wroclaw, Poland., Wang W; Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Neurology, Headache Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China., Wells-Gatnik W; Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.

Publikováno v: The journal of headache and pain [J Headache Pain] 2024 Dec 05; Vol. 25 (1), pp. 214. Date of Electronic Publication: 2024 Dec 05.

Erenumab escalation in migraine - double dose without additional benefit - a retrospective experience.

Autor: Heintz S; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Storch P; Headache Center Jena, Department of Neurology, University Hospital Jena, Jena, Germany., Burow P; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Maier P; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany., Obermann M; Department of Neurology, Klinikum Weser-Egge, Höxter, Germany., Stoessel G; Headache Center Jena, Department of Neurology, University Hospital Jena, Jena, Germany., Kraya T; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany.; Department of Neurology, Hospital St. Georg, Leipzig, Germany., Naegel S; Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany. steffen.naegel@medizin.uni-halle.de.; Department of Neurology, Alfried Krupp Krankenhaus Essen, Alfried-Krupp-Straße 21, 45131, Essen, Germany. steffen.naegel@medizin.uni-halle.de.

Publikováno v: Acta neurologica Belgica [Acta Neurol Belg] 2024 Oct; Vol. 124 (5), pp. 1663-1670. Date of Electronic Publication: 2024 Jul 27.